Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-07
2006-03-07
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S002600, C530S327000, C530S328000
Reexamination Certificate
active
07008925
ABSTRACT:
A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.
REFERENCES:
patent: 5731408 (1998-03-01), Hadley et al.
Szardenings et al. 1997. Journal of Biol. Chem. vol. 272, No. 44, pp. 27943-27948.
Bagutti, C. et al., “[111In] -DTPA-Labeled Analogues of α-Melanocyte-Stimulating Hormone for Melanoma Targeting: Receptor Binding In Vitro and In Vivo,”Int. J. Cancer 58:749-755, Wiley-Liss, Inc. (1994).
Bhardwaj, R.S. et al., “Pro-Opiomelanocortin-Derived Peptides Induce IL-10 Production in Human Monocytes,”J. Immunol. 156:2517-2521, The American Association of Immunologists (1996).
Cone, R.D. et al., “The Melancortin Receptors: Agonists, Antagonists, and the Hormonal Control of Pigmentation,”Recent Prog. Horm. Res. 51:287-317, The Endocrine Society (1996).
De Wied, D. and Jolles, J., “Neuropeptides Derived From Pro-Opiocortin: Behavioral, Physiological, and Neurochemical Effects,”Physiol. Rev. 62:976-1059, The American Physiological Society (1982).
Eberle, A.N., “Structure-Activity Relationships of the Melanotropins,” inThe Melanotropins: Chemistry, Physiology and Mechanisms of Action, Eberle, A.N., Ed., S. Karger Publishing, Basel, Switzerland, pp. 333-379 (1988).
Gonindard, C. et al., “The Administration of an α-MSH Analogue Reduces the Serum Release of IL-1α and TNFα Induced by the Injection of a Sublethal Dose of Lipopolysaccharides in the BALB/c Mouse,”Pigment Cell Res. 9:148-153, Munksgaard (1996).
Gruber, K.A. and Callahan, M.F., “ACTH- (4-10) through γ-MSH: evidence for a new class of central autonomic nervous system-regulating peptides,”Am. J. Physiol. 257:R681-R694, The American Physiological Society (1989).
Hartmeyer, M. et al., “Human Dermal Microvascular Endothelial Cells Express the Melanocortin Receptor Type 1 and Produce Increased Levels of IL-8 upon Stimulation with α-Melanocyte-Stimulating Hormone,”J. Immunol. 159:1930-1937, The American Association of Immunologists (Aug. 1997).
Hnatowich, M.R. et al., “ACTH receptors in nervous tissue. High affinity binding-sequestration of [125I] [Phe2,Nle4] ACTH 1-24 in homogenates and slices from rat brain,”Can. J. Physiol. Pharmacol. 67:568-576, National Research Council of Canada (1989).
Hol, E.M. et al., “Protection by an ACTH4-9Analogue Against the Toxic Effects of Cisplatin and Taxol on Sensory Neurons and Glial Cells In Vitro,”J. Neurosci. Res. 39:178-185, Wiley-Liss, Inc. (1994).
Hruby, V.J. et al., “Cyclic Lactam α-Melanotropin Analogues of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10] α-Melanocyte-Stimulating Hormone- (4-10) -NH2with Bulky Aromatic Amino Acids at Position 7 Show High Antagonist Potency and Selectivity at Specific Melanocortin Receptors,”J. Med. Chem. 38:3454-3461, American Chemical Society (1995).
Klein, M.C. et al., “Pressor and Cardioaccelerator Effects of Gamma MSH and Related Peptides,”Life Sci. 36:769-775, Pergamon Press (1985).
Knittel, J.J. et al., “Structure-Activity Studies of Highly Potent Cyclic [Cys4,Cys10]Melanotropin Analogues,”J. Med. Chem. 26:125-129, American Chemical Society (1983).
Lichtensteiger, W. et al., “Pre- and Postnatal Ontogeny of [125I]Nle4,D-Phe7-α-MSH Binding Sites in Rat Brain,”Ann. N.Y. Acad. Sci. 680:652-654, New York Academy of Sciences (1993).
Lin, S.-Y., et al. “A γ-Melanocyte Stimulating Hormone-like Peptide Causes Reflex Natriuresis After Acute Unilateral Nephrectomy,”Hypertension 10:619-627, American Heart Association (1987).
Murphy, J.R. et al., “Genetic construction, expression and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein,”Proc. Natl. Acad. Sci. USA 83:8258-8262, National Academy of Sciences (1986).
Prusis, P. et al., “A Three Dimensional Model for the Interaction of MSH with the Melanocortin-1 Receptor,”Biochem. Biophys. Res. Commun. 210:205-210, Academic Press Inc. (1995).
Sawyer, T.K. et al., “4-Norleucine, 7-o-phenylalanine-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity,”Proc. Natl. Acad. Sci. USA 77:5754-5758, National Academy of Sciences (1980).
Sawyer, T.K. et al., “[half-Cys4,half-Cys10] -α-Melanocyte-stimulating hormone: A cyclic α-melanotropin exhibiting superagonist biological activity,”Proc. Natl. Acad. Sci. USA 79:1751-1755, National Academy of Sciences (1982).
Tatro, J.B. et al., “Interaction of an α-Melanocyte-stimulating Hormone-Diphtheria Toxin Fusion Protein with Melanotropin Receptors in Human Melanoma Metastases,”Canc. Res. 52:2545-2548, American Association for Cancer Research (1992).
Thielemans, K.M.M., “Immunothrapy with Bispecific Antibodies,”Verh. K. Acad. Geneeskd. Belg. 57:229-248, Paleis Der Academein (1995).
Wiegant, V.M. et al., “Intracerebroventricular ACTH Activates the Pituitary-Adrenal System:Dissociation from a Behavioral Response,”Life Sci. 25:1791-1796, Pergamon Press (1979).
Schiöth, H.B. et al., “Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes,”European Journal of Pharmacology 319:369-373, Elsevier Science B.V. (Feb. 1997).
Szardenings, M. et al., “Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1,”J. Biol. Chem. 272: 27943-27948, The American Society for Biochemistry and Molecular Biology, Inc. (Oct. 1997).
Muceniece Ruta
Mutule Ilze
Mutulis Felikss
Szardenings Michael
Wikberg Jarl
Action Pharma A/S
Campell Bruce R.
Chism B. Dell
Cooper Iver P.
LandOfFree
Melanocortin 1 receptor selective compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanocortin 1 receptor selective compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin 1 receptor selective compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553996